This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytos Biotechnology Announces Full Year 2012 Financial Results

SCHLIEREN, Switzerland, February 14, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today presented its full year 2012 financial results.

Full year consolidated financial figures 2012:

Balance Sheet

Funds available for financing the Company's operations amount to CHF 28.70 million as per December 31, 2012, and include cash and cash equivalents, financial assets and trade and other receivables. They were slightly lower than at the end of December 31, 2011 ( CHF 28.82 million). This net change is composed of cash increased by CHF 33.58 million due to funds being raised in the form of equity and debt as well as payments from collaboration partners of CHF 1.10 million and other payments of CHF  0.25 million. Cash decreased mainly due to the partial repayment of the convertible bonds (CHF  16.14 million) which were restructured, due to convertible bonds being purchased as well as funds ( CHF 14.62 million) mainly being spent on on-going operating activities.

As of December 31, 2012, convertible bonds with a nominal value of CHF 13.17 million maturing in February 2015 are outstanding and not held by Cytos. In addition, convertible loan notes of CHF  6.63  million are outstanding as per December 31, 2012 which are coming due for repayment in February 2015.


Revenues decreased from CHF 1.57 million in 2011 to CHF 1.10 million in 2012. In 2012 the revenue stems from license fees from Novartis of CHF 1.00 million and revenue from a technology transfer of CHF 0.10 million. In 2011 the revenue was mainly derived from licence fees from Novartis of CHF  1.00  million, as it was the case in 2012, and revenue from former contract partners.

Cash burn

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs